Terazosin treatment suppresses basic fibroblast growth factor expression in the rat ventral prostate

Clinical and Investigative Medicine

Volumn 32, Issue 1, 2009, Pages

  Mitropoulos, Dionisios ^a   Kyroudi Voulgari, Aspasia ^a   Christelli, Evangelia ^a   Zervas, Anastasios ^a   Karayannacos, Panagiotis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BASIC FIBROBLAST GROWTH FACTOR; TERAZOSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROSTATE VENTRAL LOBE; PROTEIN EXPRESSION; RAT; STROMA CELL; TISSUE SECTION; WESTERN BLOTTING;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BLOTTING, WESTERN; FIBROBLAST GROWTH FACTOR 2; IMMUNOHISTOCHEMISTRY; MALE; PRAZOSIN; PROSTATE; RATS; RATS, WISTAR;

EID: 59649092202     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976; 48:255-63.
2. Lepor H. Role of long-acting selective alpha-1 blockers in the treatment of benign prostate hyperplasia. Urol Clin North Am 1990; 17:651-9.
3. Lee C, Cockett A, Cussenot O, Griffiths K, Isaacs W, Schalken J: Regulation of prostate growth. In: Chatelain C, Denis L, Foo KT, Khoury S, Mc Connell J (eds). Proceedings of the 5th International Consultation on BPH, Plymbridge Distributors Ltd, Plymouth, U.K. 2000; 79-106.
4. Wang JM, McKenna KE, McVary KT, Lee C. Requirement of innervation for maintenance of structural and functional integrity in the rat prostate. Biol Reprod 1991; 44:1171-6.
5. McVary KT, Razzaq A, Lee C, Venegas MF, Rademaker A, McKenna KE. Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 1994; 51:99-107.
6. Lujan M, Paez A, Llanes L, Angulo J, Berenguer A. Role of autonomic innervation in rat prostatic structure maintenance: a morphometric analysis. J Urol 1998; 160:1919-23.
7. Marinese D, Patel R, Walden PD. Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice. Prostate 2003; 54:230-7.
8. Matityahon A, Rosenzweig N, Colomb E. Rapid proliferation of prostatic epithelial cells in spontaneously hypertensive rats: a model of spontaneous hypertension and prostate hyperplasia. J Androl 2003; 24:263-9.
9. Tong YC, Hung YC, Lin SY, Cheng JT. The norepinephrine tissue concentration and neuropeptide Y immunoreactivity in genitourinary organs of the spontaneously hypertensive rat. J Auton Nerv Syst 1996; 56:215-8.
10. Smith P, Rhodes NP, Beesley C, Ke Y, Foster CS. Prostatic stromal cell phenotype is directly modulated by norepinephrine. Urology 1998; 51:663-70.
11. Smith P, Rhodes NP, Ke Y, Foster CS. Influence of the α1-adrenergic antagonist, doxazosin, on noradrenalineinduced modulation of cytoskeletal proteins in cultured hyperplastic prostatic stromal cells. Prostate 1999; 38:216-27.
12. Boesch ST, Corvin S, Zhang J, Rogatsch H, Bartsch G, Klocker H. Modulation of the differentiation status of cultured prostatic smooth muscle cells by an α1-adrenergic receptor antagonist. Prostate 1999; 39:226-33.
13. Lin VK, Benaim E, McConnell JD. Alpha-blockade downregulates myosin heavy chain gene expression in human benign hyperplasia. Urology 2001; 57:170-5.
14. Yang G, Timme TL, Park SH, Wu X, Wyllie MG, Thompson TC. Transforming growth factor ß1 transduced mouse prostate reconstitutions: II.Induction of apoptosis by doxazosin. Prostate 1997; 33:157-63.
15. Kyprianou N, Litvak JP, Borkowski A, Alexander R, Jacobs SC. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 1998; 159:1810-5.
16. Chon JK, Borkowski A, Partin AW, Isaacs JT, Jacobs SC, Kyprianou N. α1-Adrenoreceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 1999; 161:2002-8.
17. Turkeri LN, Ozyurek M, Erser D, Akdas A. Apoptotic regression of prostatic tissue induced by short-term doxazosin treatment in benign prostatic hyperplasia. Arch Esp Urol 2001; 54:191-6.
18. Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 2003; 169:1520-5.
19. Ilio KY, Park II, Pins MR, Kozlowski JM, Lee C. Apoptotic activity of doxazosin on prostate stroma in vitro is mediated through an autocrine expression of TGF-ß 1. Prostate 2001; 48:131-5.
20. Glassman DT, Chon JK, Borkowski A, Jacobs SC, Kyprianou N. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-ß expression in benign prostatic hyperplasia. Prostate 2001; 46:45-51.
21. Glassman DT, Borkowski A, Jacobs SC, Kyprianou N. Effect of doxazosin mediated alpha-1 blockade on TGF-β and p27 expression in benign prostatic hyperplasia. J Urol 2000; 163(suppl):228.
22. Guo Y, Kyprianou N. Restoration of transforming growth factor ß signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res 1999; 59:1366-71.
23. Mitropoulos D, Papakonstantinou E, Aletras AJ et al. Terazosin modifies the content of glycosaminoglycans and the activity of matrix metalloproteinase 2 in the rat ventral prostate. Eur Urol 2007; 51:447-56.
24. Kassen AE, Sensibar JA, Sintich SM, Pruden SJ, Kozlowski JM, Lee C. Autocrine effect of DHT on FGF signaling and cell proliferation in LNCaP cells : role of heparin/heparan-degrading enzymes. Prostate 2000; 44:124-32.
25. Cunha GR, Alarid ET, Turner T, Donjacour AA, Boutin EL, Foster BA. Normal and abnormal development of the male urogenital tract: role of androgens, mesenchymal-epithelial interactions, and growth factors. J Androl 1992; 13:465-75.
26. Culig Z, Hobisch A, Cronauer MV et al. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996; 28:392-405.
27. Steiner MS. Role of peptide growth factors in the prostate: a review. Urology 1993; 42:99-110.
28. Ropiquet F, Giri D, Lamb DJ, Ittmann M. FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. J Urol 1999; 162:595-9.
29. Dow JK, DeVere White RW. Fibroblast growth factor 2 its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology 2000; 55:800-6.
30. Smith PK, Krohn RI, Hermanson GT et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150:76-85.
31. Laemli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-5.
32. Maniatis T, Fritch EF, Sambrook KJ: Detection and Analysis of proteins expressed from cloned genes. In: Maniatis T, Fritch EF, Sambrook KJ (eds). Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor, 1982; 18.47-18.58.
33. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1979; 76:4350-4.
34. Maniatis T, Fritsch EF, Sambrook KJ: Detection and Analysis of proteins expressed from cloned genes. In: Maniatis T, Fritsch EF, Sambrook KJ (eds). Molecular cloning: A Laboratory Manual, New York: Cold Spring Harbor, 1982; 18.60-18.75.
35. Snyder DL, Pollard M, Wostmann BS, Luckert P. Life span, morphology and pathology of diet-restricted germ-free and conventional Lobund-Wistar rats. J Gerondol 1990; 45:B52-8.
36. Story MT. Regulation of prostate growth by fibroblast growth factors. World J Urol 1995; 13:297-305.
37. Lepor H, Williford WO, Barry MJ et al, for the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335:533-9.
38. Lujan M, Ferruelo A, Paez A, Moreno A, Berenguer A. Prostate apoptosis after doxazosin treatment in the spontaneous hypertensive rat model. BJU Int 2004; 93:410-4.
39. Abraham JA, Whang JL, Tumolo A et al. Human basic fibroblast growth factor: Nucleotide sequence and genomic organization. EMBO J 1986; 5:2523-8.
40. Story MT, Hopp KA, Molter M, Meier DA. Characterization of FGF-receptors expressed by stromal and epithelial cells cultured from normal and hyperplastic prostates. Growth factors 1994; 10:269-80.
41. Sherwood ER, Fong CJ, Lee C, Kozlowski JM. Basic fibroblast growth factor: A potential mediator of stromal growth in the human prostate. Endocrinology 1992; 130:2955-63.
42. Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP. Thrombospondin-I, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001; 49:293-305.
43. Saksela O, Moscatelli D, Sommer A, Rifkin DB. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988; 107:743-51.
44. Zhao H, Lai F, Nonn L, Brooks JD, Peehl DM. Molecular targets of doxazosin in human prostatic stromal cells. Prostate 2005; 62:400-10.
45. Drewa T, Wolski Z, Misterek B, Debski R, Styczynski J. The influence of α-antagonist on the expression pattern of TNF receptor family in primary culture of prostate epithelial cells from BPH patients. Prost Cancer Prost Dis 2008; 11:88-93.
46. Nakamura H, Itakura C. Influence of terazosin on the epithelium of prostate gland of spontaneously hypertensive rats. J Toxicol Pathol 1992; 5:101-4.
47. Keledjian K, Borkowski A, Kim G, Isaacs JT, Jacobs SC, Kyprianou N. Reduction of human prostate tumor vascularity by the alpha1-adrenoreceptor antagonist terazosin. Prostate 2001; 48:71-8.
48. Friesel RE, Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 1995; 9:9919-25.